The activation of signalling pathways involving phosphoinositide 3-kinase (PI3K) has a key role in tumour cell biology, but clinical trials of PI3K inhibitors have had limited success. In their Review on page 140, Fruman and Rommel highlight how lessons learned from clinical trial failures and an improved understanding of PI3K signalling pathways could bolster the field. In particular, they advocate that patient selection, a better understanding of immune modulation and improved use of combination therapies could advance therapeutics that target PI3K. Here in Table 1 we highlight international patent applications published in the past year related to PI3K. Data were researched using the Espacenet database.

Table 1 Selected patent applications related to PI3K
Full size table